Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NASDAQ:NVNO NASDAQ:PETV NASDAQ:POAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.38+5.6%$0.44$0.35▼$1.22$22.62M1.39117,464 shs55,743 shsNVNOenVVeno Medical$10.97+1.5%$10.64$8.67▼$184.45$7.21M1.0914,463 shs5,299 shsPETVPetVivo$0.77+0.2%$0.79$0.60▼$1.69$28.95M1.2310,711 shs9,702 shsPOAIPredictive Oncology$6.87+1.6%$6.84$0.71▼$16.54$23.32M1.35473,545 shs160,624 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents+5.58%+0.03%-13.28%-38.79%-63.10%NVNOenVVeno Medical+1.53%-4.32%+9.65%-15.07%-93.70%PETVPetVivo+0.20%+1.32%-3.75%-1.28%-3.75%POAIPredictive Oncology0.00%-6.66%-3.51%+48.70%-42.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.38+5.6%$0.44$0.35▼$1.22$22.62M1.39117,464 shs55,743 shsNVNOenVVeno Medical$10.97+1.5%$10.64$8.67▼$184.45$7.21M1.0914,463 shs5,299 shsPETVPetVivo$0.77+0.2%$0.79$0.60▼$1.69$28.95M1.2310,711 shs9,702 shsPOAIPredictive Oncology$6.87+1.6%$6.84$0.71▼$16.54$23.32M1.35473,545 shs160,624 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents+5.58%+0.03%-13.28%-38.79%-63.10%NVNOenVVeno Medical+1.53%-4.32%+9.65%-15.07%-93.70%PETVPetVivo+0.20%+1.32%-3.75%-1.28%-3.75%POAIPredictive Oncology0.00%-6.66%-3.51%+48.70%-42.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.381,314.10% UpsideNVNOenVVeno Medical 2.33HoldN/AN/APETVPetVivo 0.00N/AN/AN/APOAIPredictive Oncology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest NVNO, PETV, CTSO, and POAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026NVNOenVVeno Medical Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/6/2026CTSOCytosorbents Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/6/2026NVNOenVVeno Medical LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/30/2026NVNOenVVeno Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/15/2026NVNOenVVeno Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$37.06M0.64N/AN/A$0.09 per share4.22NVNOenVVeno MedicalN/AN/AN/AN/A$41.38 per shareN/APETVPetVivo$1.05M27.67N/AN/A($0.03) per share-25.67POAIPredictive Oncology$1.66M14.01N/AN/A($0.46) per share-14.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$8.20M-$0.19N/A12.67N/A-31.85%-235.57%-37.88%8/6/2026 (Estimated)NVNOenVVeno Medical-$19.47M-$25.54N/AN/AN/AN/A-66.39%-60.42%7/30/2026 (Estimated)PETVPetVivo-$10.95M-$0.38N/AN/AN/A-902.82%-4,813.07%-281.78%8/13/2026 (Estimated)POAIPredictive Oncology-$12.66M-$13.50N/AN/AN/A-5,065.23%-732.73%-235.55%N/ALatest NVNO, PETV, CTSO, and POAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026N/APETVPetVivo-$0.08N/AN/AN/A$0.01 millionN/A8/6/2026Q2 2026CTSOCytosorbents-$0.05N/AN/AN/A$9.39 millionN/A7/30/2026N/ANVNOenVVeno Medical-$4.69N/AN/AN/A$1.00 millionN/A5/13/2026Q1 2026CTSOCytosorbents-$0.06-$0.08-$0.02-$0.08$9.40 million$8.86 million5/7/2026Q1 2026NVNOenVVeno Medical-$8.40-$5.89+$2.51-$5.89$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/APOAIPredictive OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents4.701.090.81NVNOenVVeno MedicalN/A11.8911.89PETVPetVivo0.020.420.47POAIPredictive OncologyN/A0.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%NVNOenVVeno Medical34.71%PETVPetVivo24.55%POAIPredictive Oncology9.04%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.80%NVNOenVVeno Medical15.00%PETVPetVivo10.84%POAIPredictive Oncology1.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.84 million57.94 millionOptionableNVNOenVVeno Medical30670,000568,000OptionablePETVPetVivo2037.59 million19.06 millionNot OptionablePOAIPredictive Oncology303.39 million3.35 millionNot OptionableNVNO, PETV, CTSO, and POAI HeadlinesRecent News About These CompaniesPredictive Oncology announces name change to Axe ComputeDecember 12, 2025 | msn.comPredictive Oncology rebrands to Axe Compute Inc.December 11, 2025 | msn.comPredictive Oncology Regains Nasdaq ComplianceDecember 2, 2025 | tipranks.comPredictive Oncology regains compliance with Nasdaq minimum stockholder equityDecember 2, 2025 | msn.comPredictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementDecember 2, 2025 | markets.businessinsider.comPredictive Oncology Regains Nasdaq Compliance with InvestmentsNovember 20, 2025 | tipranks.comPredictive Oncology Expands into Digital Asset ManagementNovember 20, 2025 | msn.comPredictive Oncology Inc. (POAI) Q3 2025 Earnings Call Prepared Remarks TranscriptNovember 17, 2025 | seekingalpha.comPredictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset StrategyNovember 14, 2025 | globenewswire.comAI in Predictive Toxicology Market Outlook 2025–2032: Strong CAGR of 29.7% with USD 3,925.5 Million ValuationNovember 11, 2025 | finance.yahoo.comPredictive Oncology Updates ATM Offering ProgramOctober 29, 2025 | tipranks.comPredictive Oncology files to sell 5.97M shares of common stock for holdersOctober 22, 2025 | msn.comAethir's $344M GPU DAT Looks To Move Crypto Treasuries From Michael Saylor's Strategy Model to Something More SustainableOctober 21, 2025 | finance.yahoo.comPredictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury StrategyOctober 14, 2025 | globenewswire.comPredictive Oncology Secures $343.5 Million Investment to Launch World’s First Strategic Compute Reserve and Enhance AI-Driven Drug Discovery EffortsOctober 8, 2025 | quiverquant.comQPredictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury StrategyOctober 8, 2025 | globenewswire.comPredictive Oncology Announces $344.4M Private PlacementsSeptember 30, 2025 | msn.comPredictive Oncology Stock Receives Significant Investor Interest Today – Here Are Two Important DevelopmentsSeptember 30, 2025 | msn.comPenny stock jumps 200% on thrilling crypto announcementSeptember 29, 2025 | msn.comPredictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) TokensSeptember 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVNO, PETV, CTSO, and POAI Company DescriptionsCytosorbents NASDAQ:CTSO$0.38 +0.02 (+5.58%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$0.36 -0.02 (-6.08%) As of 08:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.enVVeno Medical NASDAQ:NVNO$10.96 +0.17 (+1.53%) Closing price 07/20/2026 03:58 PM EasternExtended Trading$11.14 +0.18 (+1.63%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. PetVivo NASDAQ:PETV$0.77 +0.00 (+0.20%) As of 07/20/2026 03:12 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Predictive Oncology NASDAQ:POAI$6.87 +0.11 (+1.63%) As of 07/17/2026Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? IBM Just Had Its Worst Day Ever—What Earnings Must Prove AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Oracle Is One Step From Junk—Can It Afford the AI Boom? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
